Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | AGXT | P21549 | 2/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.54 |
| ▸ | HTR3B | O95264 | 2/20 | 0.54 |
| ▸ | HTR3A | P46098 | 2/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301781 | 0.93 | PNMT (0.58) | PNMTTAAR1CYP3A4IDO1AGXT | |
| Ammonia Solution, Strong SCHEMBL18010559 | 0.91 | PNMT (0.56) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL2093970 | 0.91 | PNMT (0.56) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL25720257 | 0.87 | PNMT (0.52) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL8993096 | 0.87 | PNMT (0.52) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL14931455 | 0.87 | GRIN2B (0.53) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL14685891 | 0.87 | TAAR1 (0.53) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL10876787 | 0.87 | PNMT (0.52) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL1501368 | 0.85 | ALDH1A1 (0.55) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL3022914 | 0.85 | PNMT (0.50) | PNMTTAAR1CYP3A4IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | claimed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | claimed |
| US-5276132-A | Polyamic acid or polyimide having a steroidal skeleton providing a pretilt angle of 3 to 90 degrees; SBE(super twisted birefringence effect) and SH(super homeotropic) devices | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-4400520-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PRODUCING OLEFIN POLYMER | The University of Tokyo (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023037849-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PRODUCING OLEFIN POLYMER | 国立大学法人 東京大学 | 2023-03-16 | — | — | WO | disclosed |
| EP-3426656-B1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| WO-2017153919-A1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2017-09-14 | — | — | WO | disclosed |
| CN-102344816-B | Liquid crystal alignment agent, liquid crystal alignment film prepared from same and liquid crystal display element | CHI MEI CORP | 2014-02-19 | — | — | CN | disclosed |
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8299072-B2 | Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-30 | — | — | US | disclosed |
| EP-0455587-A1 | New polymers and hard gas-permeable contact lenses made therefrom | CIBA-GEIGY AG (CH) | 1991-11-06 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4777251-A | CONDENSATION OF TITANIUM TETRACHLORIDE AND O-PHTHALODINITRILE, THEN HYDROLYSIS | MITSUBISHI KASEI CORPORATION (JP) | 1988-10-11 | — | — | US | disclosed |
| US-4304591-A | A HIGH-STRENGTH GEL OF MALEIMIDE-MODIFIED POLYOXYPROPYLENE OR -TETRAMETHYLENE GLYCOL CROSSLINKED BY A WATER-SOLUBLE OLEFIN; SUSTAINED RELEASE | CIBA-GEIGY CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
| US-4277582-A | MEMBRANES AND CARRIERS FOR SUSTAINED RELEASE | CIBA-GEIGY CORPORATION (US) | 1981-07-07 | — | — | US | disclosed |
| US-4224427-A | HYDROPHILIC MONOMER, POLYOLEFINIC MACROMER CROSSLINKER, METAL HYDROXIDE GEL | CIBA-GEIGY CORPORATION (US) | 1980-09-23 | — | — | US | disclosed |
| US-4192827-A | IN A DELAMINATED MATRIX OF A TRANSITITION METAL DICHALCOGENIDE | CIBA-GEIGY CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
| US-4177056-A | CROSSLINKED; SUSTAINED RELEASE | CIBA-GEIGY CORPORATION (US) | 1979-12-04 | — | — | US | disclosed |
| US-4136250-A | CROSSLINKED, ADDITION MONOMER OR POLYMER | CIBA-GEIGY CORPORATION (US) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1B, CACNA1C, ORAI1 | PNMT 2489/4885TAAR1 3270/4885CYP3A4 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.